HELIA BIOMONITORING BV

Their core work

Helia Biomonitoring is a Dutch biotech company specialising in nanophotonic biosensing — developing sensor platforms that detect biological molecules at the single-molecule level using optical and plasmonic principles. Their work bridges molecular engineering and medical diagnostics: they design affinity-based molecular switches (leveraging protein engineering and DNA nanotechnology) that change their optical signature when they bind a target biomarker, enabling continuous, real-time monitoring of patient health. In the medical device space they have contributed to safety testing frameworks for nanotechnology-enabled diagnostics, ensuring such technologies meet regulatory requirements before reaching patients. Their commercial aim appears to be translating these lab-scale sensing breakthroughs into deployable, personalised monitoring devices.

What they specialise in

How they've shifted over time

In their earliest H2020 project (starting 2019), Helia's focus was firmly on the medical device and regulatory side of nanotechnology: safety testing, compliance frameworks for in vitro diagnostics, and handling nanomaterials in a health-technology context. By 2021 their keyword profile shifted substantially toward the fundamental engineering of sensing molecules — molecular switches, DNA nanotechnology, protein engineering, and the optical physics of nanoplasmonics — indicating a move from applied regulatory work toward core platform technology development. The trajectory is clear: they are building proprietary biosensor architectures that could underpin next-generation continuous diagnostics, moving from validating others' technologies to owning the sensing layer themselves.

Helia is moving from regulatory/safety support roles toward owning a differentiated biosensing technology platform, making them an increasingly interesting partner for diagnostics companies, wearable health tech developers, and anyone needing ultra-sensitive continuous biomarker detection.

How they like to work

Helia has participated exclusively as a consortium partner — never as coordinator — across both projects, suggesting they contribute a specialist technical capability rather than managing large programmes. Their 44 unique partners across 19 countries over just two projects indicates they slot into large, multi-stakeholder consortia rather than small bilateral arrangements. This profile is typical of a niche technology provider brought in to supply a specific sensing or characterisation competence that generalist partners cannot offer internally.

Despite only two projects, Helia has built an unusually wide network of 44 unique partners spanning 19 countries — a sign they participate in large pan-European consortia. No single geographic concentration is evident from the data, pointing to broad European research connectivity rather than a regional cluster.

What sets them apart

Helia sits at a rare intersection: they combine the physics of nanoplasmonics and optical detection with the chemistry of engineered molecular switches and DNA nanotechnology — a combination that very few companies outside major research universities can field. Based in Eindhoven, they benefit from proximity to one of Europe's densest high-tech ecosystems (ASML, Philips spin-offs, TU/e), which likely shapes both their instrumentation access and their industrial networks. For a consortium that needs a credible, industry-oriented partner to translate nanophotonic sensing concepts toward a real product, Helia fills a gap that academic labs typically cannot.

Highlights from their portfolio

• CONSENSE
  Most technically ambitious project — the concept of molecularly engineered nanoswitches for continuous personalised biosensing represents a potential platform technology with broad commercial applicability across diagnostics and health monitoring.
• SAFE-N-MEDTECH
  Largest funding received (EUR 365,662) and directly addresses EU regulatory safety requirements for nano-enabled medical devices, giving Helia credibility in compliance-critical markets.